Table 3 Means, standard deviations, mean differences, confidence intervals and effect sizes of the variables related to the hand strength and the EMG activity in all the time points.

From: A randomised clinical trial comparing 35 Hz versus 50 Hz frequency stimulation effects on hand motor recovery in older adults after stroke

Measure

Control group (n  = 20)

35 Hz NMES (n  = 21)

50 Hz NMES (n  = 20)

Strength (kgf)

Testing time

Mean (SD)

MD (CI 95%)

ES (d)

Mean (SD)

MD (CI 95%)

ES (d)

Mean (SD)

MD (CI 95%)

ES (d)

Grip strength

Baseline

4.80 (6.30)

  

5.83 (4.70)

  

3.81 (3.01)

  

1-month

5.35 (7.05)

− 0.55 (− 1.66, 0.56)

− 0.08

7.00 (4.92)

− 1.16 (− 2.25, − 0.07)*

− 0.25

4.71 (3.31)

− 0.90 (− 2.01, 0.21)

− 0.29

2-months

5.34 (6.31)

− 0.53 (− 1.67, 0.59)

− 0.08

7.71 (5.08)

− 1.88 (− 2.99, − 0.77)*

− 0.40

6.09 (3.37)

− 2.27 (− 3.41, − 1.13)*

− 0.73

Follow-up

5.95 (7.15)

− 1.15 (− 2.38, 0.08)

− 0.17

8.52 (5.06)

− 2.69 (− 3.89, − 1.48)*

− 0.56

6.24 (3.68)

− 2.42 (− 3.66, − 1.18)*

− 0.74

Pinch strength

Baseline

2.09 (2.39)

  

2.44 (2.12)

  

1.67 (1.55)

  

1-month

2.31 (2.40)

− 0.22 (− 0.64, 0.19)

− 0.09

3.02 (2.04)

− 0.58 (− 0.99, − 0.17)*

− 0.28

2.36 (1.84)

− 0.69 (− 1.11, − 0.27)*

− 0.41

2-months

2.69 (2.49)

− 0.60 (− 1.16, − 0.03)*

− 0.25

3.13 (1.97)

− 0.69 (− 1.24, − 0.13)*

− 0.34

2.71 (1.58)

− 1.05 (− 1.61, − 0.48)*

− 0.68

Follow-up

2.39 (2.07)

− 0.30 (− 0.92, 0.32)

− 0.13

3.37 (2.01)

− 0.92 (− 1.53, − 0.32)*

− 0.46

2.96 (1.98)

− 1.29 (− 1.91, − 0.67)*

− 0.74

EMG activity

Testing time

Mean (SD)

MD (CI 95%)

ES (d)

Mean (SD)

MD (CI 95%)

ES (d)

Mean (SD)

MD (CI 95%)

ES (d)

Peak A extensors (µV)

Baseline

89.95 (112.86)

  

73.24 (42.40)

  

62.75 (52.77)

  

1-month

95.45 (105.88)

− 5.50 (− 16.60, 5.60)

− 0.05

102.62 (40.22)

− 29.38 (− 40.22, − 18.54)*

− 0.73

73.85 (55.49)

− 11.10 (− 22.20, 0.00)

− 0.21

2-months

97.50 (104.31)

− 7.55 (− 22.41, 7.31)

− 0.07

116.52 (55.81)

− 43.28 (− 57.79, − 28.78)*

− 0.89

84.45 (51.09)

− 21.70 (− 36.56, − 6.83)*

− 0.43

Follow-up

92.25 (103.84)

− 2.30 (− 20.60, 16.00)

− 0.02

130.48 (58.56)

− 57.23 (− 75.10, − 39.37)*

− 1.14

101.60 (87.80)

− 38.85 (− 57.15, − 20.54)*

− 0.55

ACR extensors (%)

Baseline

42.35 (12.05)

  

39.70 (12.65)

  

45.25 (12.52)

  

1-month

43.71 (8.67)

− 1.36 (− 7.54, 4.80)

− 0.13

33.89 (10.84)

5.80 (− 0.21, 11.82)

0.50

41.64 (9.49)

3.60 (− 2.56, 9.77)

0.33

2-months

42.28 (9.54)

0.06 (− 5.52, 5.65)

0.00

30.86 (10.69)

8.83 (3.37, 14.29)*

0.77

35.07 (7.17)

10.18 (4.59, 15.77)*

1.02

Follow-up

40.90 (10.58)

1.44 (− 4.27, 7.16)

0.13

31.12 (10.62)

8.58 (2.99, 14.16)*

0.75

34.90 (8.63)

10.34 (4.62, 16.06)*

0.98

  1. SD Standard deviation, MD Mean difference (baseline minus each time), CI 95% Confidence interval 95%, ES Effect size, d Cohen’s d, A Amplitude, ACR Co− activation ratio of the antagonist; * The difference is statistically significant p < .05.